Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ZonMw: The Netherlands Organisation for Health Research and Development | OTHER |
Not provided
Not provided
Not provided
The goal of this multicenter, multi-national, multi-arm, multi-stage, randomized controlled trial, is to determine the added benefit of hyperbaric oxygen treatment (HBOT) in patients with diabetic foot ulcers and peripheral vascular disease. The main question is:
- What is the difference is the major amputation rate between the study arms?
Participants will be randomized to 20, 30 or 40 sessions of HBOT or a control group.
Objective: The primary objective is to assess the (cost-) effectiveness of HBOT in addition to standard wound care and vascular surgical treatment for patients with a DFU and leg ischaemia.
Study design: An international, multi-arm multi-stage (MAMS) design is chosen to conduct an efficient randomised clinical trial. At a planned interim analysis the best performing study arm(s) will be chosen to continue.
Study population: We need up to 544 patients with a Meggitt-Wagner stage 3 or 4 DFU and proven peripheral ischaemia.
Intervention: Patients will be randomised to receive standard care (wound treatment and surgical interventions following international guidelines) with either 0, 20, 30 or at least 40 sessions of HBOT. These sessions will compromise 90-120 minutes of HBOT at a pressure of 2.2-2.5 ATA according to international standards.
Main study parameters/endpoints: The primary endpoint is major amputation rate after 12 months. Secondary objectives are amputation-free survival, wound healing, health-related quality of life and cost-effectiveness of the interventions.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | No Intervention | Control group | |
| HBOT 20 | Experimental | Patients receiving 20 sessions of concurrent Hyperbaric oxygen treatment |
|
| HBOT 30 | Experimental | Patients receiving 30 sessions of concurrent Hyperbaric oxygen treatment |
|
| HBOT 40 | Experimental | Patients receiving at least 40 sessions of concurrent Hyperbaric oxygen treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hyperbaric oxygen | Drug | 90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA |
|
| Measure | Description | Time Frame |
|---|---|---|
| Major Amputations | Major amputations, defined as below the knee or above the knee amputations | 12 months after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Amputation-free survival | Time without amputation | Complete follow-up (up to 3 years) |
| Health-related quality of life | Quality of life based on various questionnaires (objective) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amsterdam UMC | Amsterdam | Noord-Hollad | 1105 AZ | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37230523 | Derived | Brouwer R, van der Peet R, Hoencamp R, Koelemay M, van Dieren S, van Hulst R, Ubbink D. DIONYSIUS trial: "Does increasing oxygen nurture your symptomatic ischaemic ulcer sufficiently?" Study protocol for an international multicentre randomised trial. BMJ Open. 2023 May 25;13(5):e063503. doi: 10.1136/bmjopen-2022-063503. |
Not provided
Not provided
Individual participant data that underlie the results reported in this article after deidentification (text, tables, figures and appendices).
Immediately following publication and 10 years following article publication.
Researchers who provide a scientifically good reason to require access. If approved data can be shared after the signing a Data Access Agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D016491 | Peripheral Vascular Diseases |
| D017719 | Diabetic Foot |
| D003920 | Diabetes Mellitus |
| D007511 | Ischemia |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D003925 | Diabetic Angiopathies |
| D016523 | Foot Ulcer |
Not provided
Not provided
| ID | Term |
|---|---|
| D006931 | Hyperbaric Oxygenation |
| ID | Term |
|---|---|
| D010102 | Oxygen Inhalation Therapy |
| D012138 | Respiratory Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Randomized clinical trial
Not provided
Not provided
Not provided
Not provided
| Complete follow-up (up to 3 years) |
| Complete wound healing | Complete wound healing | 12 months after inclusion |
| Pain scores | Pain scores taken by VAS questionnaire | 12 months after inclusion |
| Need for additional (vascular) interventions | Vascular interventions performed during time of inclusion | Complete follow-up (up to 3 years) |
| Cost-effectiveness and budget impact | Costs of healthcare resources, including HBOT, related to the total number of eligible patients for HBOT per year. QALYs, based on EQ-5D-5L | Complete follow-up (up to 3 years) |
| Mortality | Mortality | Complete follow-up (up to 3 years) |
| Patients perception of improvement | Quality of life based on various questionnaires (subjective) | Complete follow-up (up to 3 years) |
| TcpO2 before, during and after HBOT | Measurements of TcpO2 surrounding HBOT treatment | During intervention period |
| D007871 |
| Leg Ulcer |
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D048909 | Diabetes Complications |
| D004700 | Endocrine System Diseases |
| D003929 | Diabetic Neuropathies |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |